Polyendocrine Metabolic Ovarian Syndrome (PMOS, the new PCOS)

Moving beyond the ovaries: Why PCOS is officially now PMOS

For decades, the term Polycystic Ovarian Syndrome (PCOS) has been used to describe a collection of symptoms related to increased androgens and insulin resistance. The name implied a hallmark feature (multiple cysts on the ovaries) that was not present in all women with PCOS and simply confused the situation.

A global consensus study published in The Lancet, PCOS has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). Led by global experts (including researchers from Australia’s Monash University), this shift validates that this condition is a complex, whole-body journey rather than just a fertility or gynaecological issue.

The name “Polycystic Ovary Syndrome” was fundamentally inaccurate. The “cysts” people refer to are actually just harmless, undeveloped egg follicles that have temporarily paused in their growth due to hormonal imbalances. This outdated framing led to delayed diagnoses, fragmented healthcare, and an unfair social stigma wrapped entirely around fertility when the core problem started upstream in insulin metabolism.

The new name, PMOS, breaks down the condition more accurately:

• Polyendocrine: Reflects the widespread hormonal imbalances involved, particularly the elevation of male-type hormones (androgens, including testosterone).
• Metabolic: Formally recognises the strong relationship with insulin resistance, weight management, and cardiometabolic health.
• Ovarian: Retains the connection to the reproductive system without letting it overshadow the rest of the body.

By putting “endocrine” and “metabolic” front and center, PMOS signals to doctors everywhere that this is a multi-system condition requiring holistic care, not just a quick check-up from a gynecologist when you want to get pregnant.

The current understanding of PMOS

Today, PMOS is understood as a chronic, multi-system condition affecting roughly 1 in 8 females globally (over 170 million people). It isn’t caused by a single lifestyle flaw; it is driven by complex genetic, hormonal, and environmental factors.

Clinical features PMOS

Because PMOS is a whole-body endocrine and metabolic disorder, its symptoms extend far beyond the reproductive system. Clinically, the condition is defined by a triad of core features, which present as a wide range of physical and psychological symptoms:

Ovulatory & reproductive dysfunction: From disordered brain-ovarian communication resulting from elevated testosterone.

• Irregular or absent periods.
• Heavy periods.
• Infertility.

Hyperandrogenism: High testosterone levels drive noticeable physical changes, including:

• Hirsutism: The growth of coarse, dark hair on the face, chest, stomach, or back.
• Androgenic Alopecia: Male-pattern hair thinning or hair loss on the scalp.
• Severe Acne: Often persistent, cystic acne occurring along the jawline and chest.

Metabolic Signs: Driven by underlying insulin resistance, these features include:

• Weight gain, particularly around the abdomen, and difficulty losing it.
• Fatigue.
• Acanthosis nigricans: Darkened, velvety patches of skin typically found in body folds, such as around the back of the neck, armpits, or groin.

Psychological Impact: The chronic hormonal disruptions and distressing physical changes carry a heavy emotional toll, significantly increasing the risk for anxiety, depression, poor body image, and body dysmorphia. Concerns about infertility compound this.

Underlying mechanism: the insulin-testosterone domino effect

At the root of PMOS lies a biochemical domino effect driven by insulin resistance, which directly links metabolic health to reproductive symptoms. When your body’s cells become resistant to insulin, your pancreas compensates by pumping massive amounts of the hormone into your bloodstream. This excess insulin acts as a “double-whammy” on your ovaries and your liver, ultimately causing a surge in male hormones and stalling your menstrual cycle.

• Direct stimulation of the ovaries: While your muscle and fat cells may ignore insulin, your ovaries remain highly sensitive to it. High circulating insulin acts like a direct command signal to the theca cells inside the ovaries, stimulating them to overproduce androgens—specifically male-type hormones like testosterone.

• Shutting down the liver’s “mop”: At the same time, this high level of insulin travels to your liver and signals it to decrease the production of a crucial protein called Sex Hormone-Binding Globulin (SHBG). Think of SHBG as a molecular sponge that travels through your blood, binding to excess testosterone to keep it inactive. When insulin suppresses SHBG, there aren’t enough proteins to clean up the hormone, allowing high amounts of free, active testosterone.

• High testosterone stalls your period: Your menstrual cycle relies on a perfectly timed, delicate conversation between your brain and your ovaries. When your bloodstream has elevated free testosterone, it scrambles these chemical messages, disrupting the steady pulses of Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH). Because the signals are confused, the egg follicles inside your ovaries don’t get the proper cue to fully mature. Instead of a dominant follicle maturing and releasing an egg (typical cycle ovulation), multiple follicles freeze mid-development. Because ovulation never occurs, your body misses the hormonal trigger to shed the uterine lining, resulting in the irregular, delayed, or missed periods characteristic of the condition.

Evidence-based treatment options

When managing PMOS, the gold standard for clinical care is established by the globally recognised Monash University 2023 International Evidence-Based Guidelines. These guidelines emphasise that treatment should be patient-centred, highly tailored, and focused on long-term wellness.

Current treatment protocols typically span three main pillars:

“Lifestyle” medicine: This serves as the foundation.  Sustainable, healthy eating habits and regular physical activity to improve insulin sensitivity and boost cardiovascular health. Importantly, the guidelines notes that these habits are vital for metabolic health regardless of whether they result in weight loss.

Medical management:

• Combined Oral Contraceptive Pills (COCP): Used as a first-line medical therapy to regulate periods, protect the uterine lining, and lower androgen levels (reducing acne and excess hair). They do this in 2 main ways – by increasing SHBG production to mop up excess androgens and over-riding the communication between brain and ovary.
• Metformin: Often prescribed to directly target insulin resistance, helping lower blood glucose and manage metabolic risks.
• Anti-Androgens: Medications that block male hormones can be introduced if cosmetic symptoms like hair loss or severe hirsutism don’t improve with the pill alone.

Emotional & psychological support: Because PMOS affects mental health so profoundly, the 2023 guidelines heavily advocate for regular routine screenings for anxiety and depression, integrating counselling and stress management into standard care.

Specialised fertility care: If natural fertility is impaired.

PMOS and the menopause transition

A common misconception is that PMOS is a reproductive-aged disease that magically disappears once your periods stop. In reality, PMOS is a lifelong metabolic condition that persists well into menopause. As you transition into menopause, the way PMOS manifests shifts significantly:

• Ovarian function calms down: The hormonal fluctuations of the ovaries naturally decline with age. Many women find that their menstrual cycles actually become more regular in their late 30s and 40s as they approach menopause, and the physical appearance of the ovaries on an ultrasound changes.

• The metabolic shift can intensify: While the reproductive symptoms may ease, the metabolic risks often ramp up. Menopause naturally increases insulin resistance and alters fat distribution (often leading to more abdominal fat). For someone with PMOS, this means the risk for type 2 diabetes, high cholesterol, and cardiovascular disease can escalate after menopause.

The name change to PMOS is vital for post-menopausal women. Under the old name, healthcare providers frequently ignored the condition after a patient went through menopause. Under the new name, the focus transitions seamlessly to monitoring your cardiovascular health, checking blood sugar levels, and protecting your metabolic well-being for the long haul.

The shift from PCOS to PMOS is a massive victory for patients. It demands that the medical system treats you as a whole person—not just an ovary.

Whether you are navigating irregular periods in your twenties or managing your cardiovascular health through menopause, remember that your symptoms are real, your condition is multi-systemic, and you deserve comprehensive, evidence-based care every step of the way.